Literature DB >> 27156316

A Preliminary Study on RCN3 Protein Expression in Non-small Cell Lung Cancer.

Yu Hou, Yongchao Li, Fuxing Gong, Jiawei Jin, Aiben Huang, Qiuhong Fang, Runlin Z Ma.   

Abstract

BACKGROUND: Reticulocalbin 3 (RCN3), a member of CREC (Cab45/reticulocalbin/ ERC-45/calumenin) family protein, is located in the secretory pathway of endoplasmic reticulum (ER) of living cells. Disruption of RCN3 leads to failure of lung function in the mouse model. Although ER stress has been associated with the development of a variety of tumors, the role of RCN3 in development of non-small cell lung cancer (NSCLC) in human is unknown at present.
METHODS: In this study a total of 41 paired NSCLC specimens (cancer group) and the adjacent normal tissues (control group) were obtained from patients undergoing lung lobectomy or pneumonectomy surgeries in Beijing Shijitan Hospital, Capital Medical University. The RCN3 mRNA and protein level in each clinical sample was determined using quantitative real time-PCR and immunoblotting, respectively. Immunohistochemistry analysis was utilized to compare the protein expressional patterns of RCN3 between the two clinical sample groups.
RESULTS: Immunoblotting showed that levels of RCN3 protein in the NSCLC tissues were significantly lower than those in the control group (p < 0.001), suggesting ER stress is closely associated with the cancer cells. Accordingly, the ER stress protein GRP78 (glucose-regulated protein 78, also known as BIP) was remarkably upregulated in the cancer group (p < 0.05). Within the cancer group, a significant difference in RCN3 protein expression was observed in squamous cell carcinoma versus adenocarcinoma (p < 0.05). In the lung cancer group, however, RCN3 protein levels were not correlated with the age and the gender. In addition, RCN3 mRNA levels showed no significant difference between the cancer and the control groups, suggesting that the differential regulation of RCN3 is likely at post-transcription stage in NSCLC.
CONCLUSIONS: Our study showed that RCN3 protein level was significantly down regulated in NSCLC, suggesting a potential correlation between RCN3 protein depletion and development of NSCLC. Although the exact cause-effect relationship between RCN3 and NSCLC needs to be further investigated, the study helps to shed additional lights on the molecular regulation of the lung cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27156316     DOI: 10.7754/clin.lab.2015.150411

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy.

Authors:  Jian Ding; Yan Meng; Zelong Han; Xiaobei Luo; Xuxue Guo; Yiwen Li; Side Liu; Kangmin Zhuang
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

2.  Reticulocalbin 2 correlates with recurrence and prognosis in colorectal cancer.

Authors:  Gang Wang; Qian Wang; Yongguo Fan; Xianli He
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

3.  Rcn3 Suppression Was Responsible for Partial Relief of Emphysema as Shown by Specific Type II Alveolar Epithelial Cell Rcn3 CKO Mouse Model.

Authors:  Qianyu Zhang; Tong Wang; Jiawei Jin; Xiaoqian Shi; Aiben Huang; Zhenru Ma; Jiujie Li; Shiyu Wang; Runlin Z Ma; Qiuhong Fang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-01-26

4.  Reticulocalbin3: A Ca2+ homeostasis regulator that promotes esophageal squamous cell carcinoma progression and cisplatin resistance.

Authors:  Rui Cai; Ping Wang; Xin Zhao; Xiansheng Lu; Ruxia Deng; Xiaoyu Wang; Chang Hong; Jie Lin
Journal:  Cancer Sci       Date:  2022-08-03       Impact factor: 6.518

5.  Integrative genomics analysis identifies promising SNPs and genes implicated in tuberculosis risk based on multiple omics datasets.

Authors:  Mengqiu Xu; Jingjing Li; Zhaoying Xiao; Jiongpo Lou; Xinrong Pan; Yunlong Ma
Journal:  Aging (Albany NY)       Date:  2020-10-13       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.